{
  "PMID": "33762277",
  "OWN": "NLM",
  "STAT": "MEDLINE",
  "DCOM": "20210405",
  "LR": "20221207",
  "IS": "1757-790X (Electronic) 1757-790X (Linking)",
  "VI": "14",
  "IP": "3",
  "DP": "2021 Mar 24",
  "TI": "Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.",
  "LID": "10.1136/bcr-2020-239963 [doi] e239963",
  "AB": "Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia. A 73-year-0ld woman with COVID-19 pneumonia was treated with dexamethasone and hydroxychloroquine. Her home medications, citalopram and donepezil, were continued. The ECG prior to starting hydroxychloroquine showed normal sinus rhythm with prolonged corrected QT (QTc) of 497 ms, due to citalopram and donepezil therapy. Repeat ECG on days 3 and 4 of hydroxychloroquine therapy showed significantly prolonged QTc of 557 ms and 538 ms, respectively, despite normal serum electrolytes. All QT-prolonging medications including hydroxychloroquine were discontinued on day 4; however, she suffered a transient torsades de pointes lasting for about 15 s, which resolved before any intervention. QTc improved to 477 ms, after discontinuation of QT-prolonging medications. The patient had QTc prolongation and torsades de pointes due to therapy with multiple QT-prolonging medications. Medicine reconciliation and careful monitoring of QTc may help prevent cardiac complications in patients with COVID-19 treated with hydroxychloroquine.",
  "CI": [
    "(c) BMJ Publishing Group Limited 2021. No commercial re-use. See rights and",
    "permissions. Published by BMJ."
  ],
  "FAU": [
    "Aslam, Waqas",
    "Lamb, Carla R",
    "Ali, Nadia"
  ],
  "AU": [
    "Aslam W",
    "Lamb CR",
    "Ali N"
  ],
  "AUID": [
    "ORCID: 0000-0003-0096-5841"
  ],
  "AD": [
    "Pulmonary and Critical Care Medicine, Interventional Pulmonology, University of California San Francisco, Fresno, California, USA drwaqasaslam@yahoo.com.",
    "Pulmonary and Critical Care Medicine, Interventional Pulmonology, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.",
    "Internal Medicine & Geriatrics, Hebrew Senior Life, Harvard Medical School Affiliate, Roslindale, Massachusetts, USA."
  ],
  "LA": [
    "eng"
  ],
  "PT": [
    "Case Reports",
    "Journal Article"
  ],
  "DEP": "20210324",
  "PL": "England",
  "TA": "BMJ Case Rep",
  "JT": "BMJ case reports",
  "JID": "101526291",
  "RN": [
    "0 (Anti-Infective Agents)",
    "0DHU5B8D6V (Citalopram)",
    "4QWG6N8QKH (Hydroxychloroquine)",
    "7S5I7G3JQL (Dexamethasone)",
    "8SSC91326P (Donepezil)"
  ],
  "SB": "IM",
  "MH": [
    "Aged",
    "Anti-Infective Agents/adverse effects/therapeutic use",
    "Citalopram/adverse effects/therapeutic use",
    "Dexamethasone/*adverse effects/therapeutic use",
    "Donepezil/adverse effects/therapeutic use",
    "Drug Therapy, Combination",
    "Electrocardiography/methods",
    "Female",
    "Heart Diseases/chemically induced/prevention & control",
    "Humans",
    "Hydroxychloroquine/*adverse effects/therapeutic use",
    "Long QT Syndrome/chemically induced",
    "SARS-CoV-2",
    "Torsades de Pointes/*chemically induced",
    "*COVID-19 Drug Treatment"
  ],
  "PMC": "PMC7993211",
  "OTO": [
    "NOTNLM"
  ],
  "OT": [
    "arrhythmias",
    "pneumonia (infectious disease)",
    "unwanted effects / adverse reactions"
  ],
  "COIS": [
    "Competing interests: None declared."
  ],
  "EDAT": "2021/03/26 06:00",
  "MHDA": "2021/04/07 06:00",
  "PMCR": [
    "2021/03/24"
  ],
  "CRDT": [
    "2021/03/25 05:50"
  ],
  "PHST": [
    "2021/03/25 05:50 [entrez]",
    "2021/03/26 06:00 [pubmed]",
    "2021/04/07 06:00 [medline]",
    "2021/03/24 00:00 [pmc-release]"
  ],
  "AID": [
    "14/3/e239963 [pii]",
    "bcr-2020-239963 [pii]",
    "10.1136/bcr-2020-239963 [doi]"
  ],
  "PST": "epublish",
  "SO": "BMJ Case Rep. 2021 Mar 24;14(3):e239963. doi: 10.1136/bcr-2020-239963.",
  "abstract": "Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia. A 73-year-0ld woman with COVID-19 pneumonia was treated with dexamethasone and hydroxychloroquine. Her home medications, citalopram and donepezil, were continued. The ECG prior to starting hydroxychloroquine showed normal sinus rhythm with prolonged corrected QT (QTc) of 497 ms, due to citalopram and donepezil therapy. Repeat ECG on days 3 and 4 of hydroxychloroquine therapy showed significantly prolonged QTc of 557 ms and 538 ms, respectively, despite normal serum electrolytes. All QT-prolonging medications including hydroxychloroquine were discontinued on day 4; however, she suffered a transient torsades de pointes lasting for about 15 s, which resolved before any intervention. QTc improved to 477 ms, after discontinuation of QT-prolonging medications. The patient had QTc prolongation and torsades de pointes due to therapy with multiple QT-prolonging medications. Medicine reconciliation and careful monitoring of QTc may help prevent cardiac complications in patients with COVID-19 treated with hydroxychloroquine.",
  "doi": "10.1136/bcr-2020-239963",
  "pmid": "33762277",
  "year": "2021",
  "title": "Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.",
  "source": "pubmed",
  "full_text": "Case report\nTorsades de pointes in SARS- CoV-2 (COVID-19)\npneumonia: medicine reconciliation and careful\nmonitoring of QTc interval may help prevent\ncardiac complications\nWaqas Aslam ,1 Carla R Lamb,2 Nadia Ali3\n1Pulmonary and Critical Care SUMMARY and rhinorrhoea for 2 days. The patient was noted\nMedicine, Interventional Hydroxychloroquine has been widely prescribed to treat to be restless with intermittent agitation in the ER.\nPulmonology, University of patients with COVID-19 pneumonia. A 73- year- 0ld On initial evaluation in the ER, she was febrile with\nCalifornia San Francisco, Fresno, woman with COVID-19 pneumonia was treated with temperature 100.2\u00b0F and hypotensive with a blood\nCalifornia, USA\ndexamethasone and hydroxychloroquine. Her home pressure of 89/53 mm Hg. Oxygen saturation was\n2Pulmonary and Critical Care\nmedications, citalopram and donepezil, were continued. 90% on room air. She responded appropriately to\nMedicine, Interventional\nThe ECG prior to starting hydroxychloroquine showed fluid resuscitation with an improved blood pressure\nPulmonology, Lahey Hospital\nand Medical Center, Burlington, normal sinus rhythm with prolonged corrected QT (QTc) of 143/65 mm Hg after administration of 2 L 0.9%\nMassachusetts, USA of 497 ms, due to citalopram and donepezil therapy. normal saline. Otherwise, the physical examination\n3Internal Medicine & Geriatrics, Repeat ECG on days 3 and 4 of hydroxychloroquine was unremarkable.\nHebrew Senior Life, Harvard therapy showed significantly prolonged QTc of\nMedical School Affiliate, 557 ms and 538 ms, respectively, despite normal\nRoslindale, Massachusetts, USA serum electrolytes. All QT- prolonging medications INVESTIGATIONS\nPertinent laboratory work-u p revealed leucopenia\nincluding hydroxychloroquine were discontinued on\nCorrespondence to (white cell count 2.94\u00d7109/L), lymphopenia (abso-\nday 4; however, she suffered a transient torsades de\nDr Waqas Aslam; lute lymphocyte count 0.71\u00d7109/L), mild throm-\npointes lasting for about 15 s, which resolved before\nd rwaqasaslam@ yahoo.c om bocytopenia (platelet count 108\u00d7109/L), elevated\nany intervention. QTc improved to 477 ms, after\nlactate (2.5 mmol/L), elevated blood glucose (185\ndiscontinuation of QT-p rolonging medications. The\nAccepted 16 February 2021\nmg/dL), elevated C reactive protein (19.5 mg/L),\npatient had QTc prolongation and torsades de pointes\nnormal troponin I, normal renal and liver tests,\ndue to therapy with multiple QT- prolonging medications.\nand a negative influenza A and B test. Chest radio- Medicine reconciliation and careful monitoring of QTc\ngraph showed few bilateral pulmonary infiltrates,\nmay help prevent cardiac complications in patients with\nsuspicious for COVID-19. Nasopharyngeal swab\nCOVID-19 treated with hydroxychloroquine.\nfor COVID-19 was obtained and she was admitted\nto the hospital with sepsis and acute hypoxic respi-\nratory failure requiring oxygen supplementation at\nBACKGROUND 2\u20133 L/min via nasal cannula. The patient\u2019s home\nHydroxychloroquine is a safe and well-t olerated medications, including citalopram 20 mg daily,\nmedication, used in the management of malaria donepezil 10 mg daily and gabapentin 300 mg three\nand connective tissue disorders including rheu- times per day, were continued. The ECG prior to\nmatoid arthritis and systemic lupus erythema- starting hydroxychloroquine showed normal sinus\ntosus for decades.1 Hydroxychloroquine has been rhythm with a prolonged QTc of 497 ms (figure 1),\nwidely prescribed in the past few months to treat due to citalopram and donepezil therapy. Coro-\npatients with COVID-19 disease due to its anti- navirus SARS- CoV-2 (COVID-19) test came back\ninflammatory and antiviral properties, especially positive and she was started on dexamethasone and\nafter Gautret et al2 showed significant reduction in hydroxychloroquine monotherapy for 5 days (800\nSARS- CoV-2 viral load with hydroxychloroquine mg for 1 day followed by 400 mg for 4 days). Azith-\ntherapy. The antiviral effect of hydroxychloroquine romycin was not started due to prolonged QTc. Her\nwas proposed to be further reinforced by adding medical condition continued to decline with wors-\nazithromycin to the regimen.2 We report an inter- ening hypoxia requiring medical intensive care unit\nesting case of corrected QT (QTc) prolongation and admission. She initially required oxygen supple-\ntorsades de pointes in a patient with SARS- CoV-2 mentation via non- rebreather and high- flow nasal\n(COVID-19) pneumonia, provoked by therapy oxygen, followed by endotracheal intubation and\n\u00a9 BMJ Publishing Group with multiple QTc-p rolonging medications. mechanical ventilation. She required fentanyl and\nLimited 2021. No commercial\nre- use. See rights and propofol infusions for sedation. Echocardiogram\npermissions. Published by BMJ. CASE PRESENTATION revealed normal left and right ventricular function.\nA 73- year-o ld woman with a medical history Repeat ECG on days 3 and 4 of hydroxychloroquine\nTo cite: Aslam W,\nof diabetes mellitus type II, hyperlipidaemia, therapy showed significantly prolonged QTc of 557\nLamb CR, Ali N. BMJ Case\nRep 2021;14:e239963. dementia, depression and gastro- oesophageal ms and 538 ms (figure 2), respectively. Electrolytes\ndoi:10.1136/bcr-2020- reflux disease was sent to the emergency room (ER) including potassium, magnesium and calcium were\n239963 from an assisted living facility with fever 101.7\u00b0F normal. All QTc-p rolonging medications including\nAslam W, et al. BMJ Case Rep 2021;14:e239963. doi:10.1136/bcr-2020-239963 1\ncopyright.\nBMJ\nCase\nRep:\nfirst\npublished\nas\n10.1136/bcr-2020-239963\non\n24\nMarch\n2021.\nDownloaded\nfrom\nhttp://casereports.bmj.com/\non\nAugust\n11,\n2021\nat\nIndia:BMJ-PG\nSponsored.\nProtected\nby\nCase report\nFigure 1 ECG with prolonged QTc of 497 ms. BPM, beats per minute; Figure 3 ECG with QTc of 477 ms after discontinuation of QT-\nQTc, corrected QT. prolonging medications. BPM, beats per minute; QTc, corrected QT.\nhydroxychloroquine were discontinued on day 4, however the\nwas transitioned to comfort care on day 18 of the intensive care\npatient suffered a transient torsades de pointes lasting for about\nunit stay after a failed extubation.\n15 s, which resolved spontaneously before any intervention.\nShe had QTc prolongation and torsades de pointes, provoked\nDISCUSSION\nby multiple QT-p rolonging medications including citalopram,\nHydroxychloroquine can cause acute and chronic toxicity.\ndonepezil, propofol and hydroxychloroquine. QTc improved to\nPotential adverse effects of hydroxychloroquine include gastro-\n477 ms (figure 3) after discontinuation of hydroxychloroquine\nintestinal disturbance, skin photosensitivity, retinopathy, cardiac\nand other QT- prolonging medications. Remdesevir was not\ntoxicity, hypoglycaemia, neuropsychiatric effects including\navailable at that time for treatment of COVID-19 pneumonia.\nagitation, confusion and psychosis, and haemolysis, especially in\npatients with glucose-6- phosphate dehydrogenase deficiency.3 4\nTREATMENT\nCardiac complications from hydroxychloroquine are rare but\nQTc improved to 477 ms after discontinuation of hydroxychlo-\ncan be severe and life-t hreatening. Hydroxychloroquine- related\nroquine and other QT-p rolonging medications. QTc was moni-\ncardiac adverse effects are conduction abnormalities, ventricular tored closely with daily ECG. Serum electrolytes were closely\nhypertrophy, restrictive cardiomyopathy, heart failure, pulmo-\nmonitored and repleted as appropriate.\nnary arterial hypertension and valvular dysfunction.5 6 Various\ncardiac conduction abnormalities include first-d egree atrioven-\nOUTCOME AND FOLLOW-UP\ntricular block, second- degree atrioventricular block, complete\nThe patient\u2019s intensive care unit course was complicated by\nheart block, prolonged QTc, torsades de pointes and other\nprolonged respiratory failure, methicillin-r esistant Staphylo- ventricular arrhythmias.5 6 Risk factors for hydroxychloroquine-\ncoccus aureus pneumonia, metabolic encephalopathy, right\nassociated cardiac arrhythmia are inherited long QT syndrome,\nlower extremity deep venous thrombus and upper gastroin-\nischaemic heart disease, cardiomyopathy, congestive heart\ntestinal bleed. She did not have any recurrence of torsades de\nfailure, history of ventricular arrhythmia, unexplained syncope,\npointes or any other ventricular arrhythmia. Unfortunately, she\nfamily history of premature sudden cardiac death, polypharmacy\nwith QTc-p rolonging medications, electrolyte abnormalities\n(hypokalaemia, hypomagnesaemia, hypocalcaemia), hepatic and\nrenal failure.7\u20139\nHospitalised patients and those with risk factors for\nhydroxychloroquine- associated cardiac arrhythmia should be\nrecommended an ECG before considering hydroxychloroquine\ntherapy, unless they had one within the last 3 months.8 Patients\nwith normal QTc and no risk factors for cardiac toxicity can be\ntreated without delay.8 9 Patients with slightly prolonged QTc\n\u2265470 ms (men) or \u2265480 ms (women) but QTc <500 ms should\nbe treated with caution; with a repeat ECG in 48 and 96 hours to\nre- evaluate QTc.8 9 Patients with prolonged QTc \u2265500 ms should\nbe reassessed after correction of electrolytes and discontinuation\nof other QT-p rolonging medications.8 9 If QTc persists \u2265500 ms,\nevaluation of benefits and risks of therapy and expert consulta-\ntion may be considered.8 9 Patients on multiple QTc-p rolonging\nmedications should have a repeat ECG in 48 hours; if QTc\nincreases by \u226560 ms or becomes \u2265500 ms, re- evaluate bene-\nFigure 2 ECG with prolonged QTc of 538 ms. BPM, beats per minute; fits and risks of therapy.8 9 Citalopram, donepezil and propofol\nQTc, corrected QT. have all been associated with QTc prolongation and ventricular\n2 Aslam W, et al. BMJ Case Rep 2021;14:e239963. doi:10.1136/bcr-2020-239963\ncopyright.\nBMJ\nCase\nRep:\nfirst\npublished\nas\n10.1136/bcr-2020-239963\non\n24\nMarch\n2021.\nDownloaded\nfrom\nhttp://casereports.bmj.com/\non\nAugust\n11,\n2021\nat\nIndia:BMJ-PG\nSponsored.\nProtected\nby\nCase report\narrhythmia.10\u201313 Our patient received multiple QTc-p rolonging determined by BMJ. You may use, download and print the article for any lawful,\nmedications including citalopram, donepezil and propofol along non- commercial purpose (including text and data mining) provided that all copyright\nnotices and trade marks are retained.\nwith hydroxychloroquine, which caused significant QTc prolon-\ngation and provoked torsades de pointes. Medicine recon- ORCID iD\nciliation and careful monitoring of QTc can prevent cardiac Waqas Aslam http://o rcid. org/0 000- 0003-0 096- 5841\ncomplications in patients with COVID-19 treated with hydroxy-\nchloroquine. The role of hydroxychloroquine in COVID-19 has\nREFERENCES\nbeen evaluated in various clinical trials and recent studies do not\n1 Costedoat-C halumeau N, Hulot J-S , Amoura Z, et al. Heart conduction disorders\nsupport any clinical benefit of hydroxychloroquine therapy in\nrelated to antimalarials toxicity: an analysis of electrocardiograms in 85 patients\nCOVID-19.14\u201317\ntreated with hydroxychloroquine for connective tissue diseases. Rheumatology\n2007;46:808\u201310.\nLearning points 2 Gautret P, Lagier J- C, Parola P, et al. Hydroxychloroquine and azithromycin as a\ntreatment of COVID-19: results of an open-l abel non- randomized clinical trial. Int J\nAntimicrob Agents 2020;56:105949.\n\u25ba Citalopram, donepezil and propofol can cause QT 3 Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine\nprolongation and ventricular arrhythmia. and azithromycin in the management of SARS- CoV-2 infection. CMAJ\n\u25ba Hydroxychloroquine- associated adverse effects include 2020;192:E450\u20133.\ngastrointestinal disturbance, skin photosensitivity, 4 Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J\n2020;96:550\u20135.\nretinopathy, cardiac toxicity, hypoglycaemia and\n5 Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to\nneuropsychiatric adverse effects.\nchloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf\n\u25ba Hydroxychloroquine can cause cardiac conduction 2018;41:919\u201331.\nabnormalities including first- degree and second- degree 6 Chen C- Y, Wang F-L , Lin C- C. Chronic hydroxychloroquine use associated with QT\natrioventricular block, complete heart block, prolonged prolongation and refractory ventricular arrhythmia. Clin Toxicol 2006;44:173\u20135.\n7 Kapoor A, Pandurangi U, Arora V, et al. Cardiovascular risks of hydroxychloroquine corrected QT (QTc), torsades de pointes and other ventricular\nin treatment and prophylaxis of COVID-19 patients: a scientific statement from the\narrhythmias. Indian heart rhythm Society. Indian Pacing Electrophysiol J 2020;20:117\u201320.\n\u25ba Cardiac comorbidities, polypharmacy with QT- prolonging 8 Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug- induced\nmedications, electrolyte abnormalities, hepatic and renal ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian\nheart rhythm Society. Can J Cardiol 2020;36:948\u201351.\nfailure increase the risk of hydroxychloroquine- associated\n9 Giudicessi JR, Noseworthy PA, Friedman PA, et al. Urgent guidance for navigating\ncardiac complications.\nand circumventing the QTc- Prolonging and torsadogenic potential of possible\n\u25ba Medicine reconciliation and careful monitoring of QTc can pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc\nprevent cardiac complications in patients with COVID-19 2020;95:1213\u201321.\ntreated with hydroxychloroquine. 10 Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes,\nand psychotropic medications. Psychosomatics 2013;54:1\u201313.\n\u25ba Recent studies do not support any clinical benefit of 11 Alu\u0161\u00edk \u0160tefan, Paluch Z. [Citalopram and QT prolongation]. Vnitr Lek 2018;63:952\u20136.\nhydroxychloroquine therapy in COVID-19. 12 Takaya T, Okamoto M, Yodoi K, et al. Torsades de pointes with QT prolongation\nrelated to donepezil use. J Cardiol 2009;54:507\u201311.\n13 Abrich VA, Ramakrishna H, Mehta A, et al. The possible role of propofol in drug-\nContributors WA was involved in direct patient care with full access to the patient induced torsades de pointes: a real-w orld single-c enter analysis. Int J Cardiol\ndata and drafted the initial manuscript. CRL and NA reviewed the manuscript, 2017;232:243\u20136.\nprovided feedback and helped in the final editing of the manuscript. 14 Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status\nFunding The authors have not declared a specific grant for this research from any at 14 days in hospitalized patients with COVID-19. JAMA 2020;324:2165.\nfunding agency in the public, commercial or not- for- profit sectors. 15 RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of\nhydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med\nCompeting interests None declared. 2020;383:2030\u201340.\nPatient consent for publication Next of kin consent obtained. 16 Cavalcanti AB, Zampieri FG, Rosa RG. Hydroxychloroquine with or without\nazithromycin in mild-t o- moderate COVID-19. N Engl J Med 2020;383:2041\u201352.\nProvenance and peer review Not commissioned; externally peer reviewed.\n17 Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of\nThis article is made freely available for use in accordance with BMJ\u2019s website hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med\nterms and conditions for the duration of the covid-19 pandemic or until otherwise 2020;383:517\u201325.\nCopyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit\nhttps://www.bmj.com/company/products-services/rights-and-licensing/permissions/\nBMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.\nBecome a Fellow of BMJ Case Reports today and you can:\n\u25ba Submit as many cases as you like\n\u25ba Enjoy fast sympathetic peer review and rapid publication of accepted articles\n\u25ba Access all the published articles\n\u25ba Re-use any of the published material for personal use and teaching without further permission\nCustomer Service\nIf you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.\nVisit casereports.bmj.com for more articles like this and to become a Fellow\nAslam W, et al. BMJ Case Rep 2021;14:e239963. doi:10.1136/bcr-2020-239963 3\ncopyright.\nBMJ\nCase\nRep:\nfirst\npublished\nas\n10.1136/bcr-2020-239963\non\n24\nMarch\n2021.\nDownloaded\nfrom\nhttp://casereports.bmj.com/\non\nAugust\n11,\n2021\nat\nIndia:BMJ-PG\nSponsored.\nProtected\nby",
  "full_text_source": "sci-hub"
}